The present invention relates to the use of radium-223, particularly a pharmaceutically acceptable salt of radium-223, and combinations comprising radium-223, for the preparation of a medicament for the treatment or prophylaxis of a haematologic malignancy disease, particurlarly for the treatment of multiple myeloma thereof.